MenACWY vaccine (Menveo® or Nimenrix®): patient group direction (PGD) template

PGD template to support the national Meningococcal group A,C,W and Y (Menveo® or Nimenrix®) vaccination programme.


Meningococcal group A,C,W and Y vaccine (Menveo® or Nimenrix®) PGD template

This file may not be suitable for users of assistive technology. Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email Please tell us what format you need. It will help us if you say what assistive technology you use.


This patient group direction (PGD) template is to support the meningococcal group A,C,W and Y vaccination programme. It is valid from 1 July 2017 to 30 June 2019.

This PGD template requires further authorisation by an appropriate authorising person, relating to the class of person by whom product is to be supplied, in accordance with the Human Medicines Regulations 2012 (HMR). This may be a clinical governance or patient safety lead, who has designated responsibility for signing PGDs on behalf of the authorising body. The PGD is not legal or valid without signed authorisation in accordance with HMR 2012 schedule 16 part 2

Adoption and governance of the use of this PGD is the responsibility of the authorising organisation and provider.

Provider organisations, health professionals and immunisation practitioners should check they are working to the current PGD versions and only work to documents authorised in accordance with HMR 2012 schedule 16 part 2.

These PGDs should be used with reference to the Green Book, and Summary of Product Characteristics for the vaccine.

Published 14 July 2015
Last updated 23 May 2017 + show all updates
  1. Added revised PGD v02.00 to replace expiring v01.00 from 1 July 2017
  2. First published.